HELLERUP, Denmark, Oct. 25, 2023 /PRNewswire/ -- UNION therapeutics A/S (UNION), a privately held, clinical stage, pharmaceutical development company focused on immunology and infectious disease, today announced that Dr. Kim D. Kjøller, CEO of UNION therapeutics will present at the seminar on clinical trials at the 7th Annual Dermatology Drug Development Summit on October 31 - November 2, 2023, in Boston, US.
HELLERUP, Denmark, Oct. 6, 2023 /PRNewswire/ -- UNION therapeutics A/S (UNION), a privately held, multi-asset, clinical stage, pharmaceutical development company focused on immunology and infectious disease, today announced acceptance of a late-breaking oral presentation at the European Academy of Dermatology and Venerology (EADV) Congress 2023 on October 11-14, 2023, in Berlin, Germany. New data from the OSIRIS investigator-initiated (IIT) proof of concept open label, single center study of oral orismilast in HS will be presented by the investigator Professor, Dr. Gregor Jemec.
Altis Labs, which develops AI-supported computational imaging to accelerate clinical trials, has raised $6 million in seed funding to further develop its technology.
UNION therapeutics to participate at Kempen Life Science Conference
The US Food and Drug Administration (FDA) has granted Fast Track designation for Union therapeutics’ oral orismilast to treat moderate-to-severe hidradenitis suppurativa (HS).
HELLERUP, Denmark, Jan. 9, 2023 /PRNewswire/ -- UNION therapeutics A/S (UNION), a privately-held, multi-asset, clinical stage, pharmaceutical development company focused on immunology and infectious disease, today announces positive topline results from the IASOS Phase 2b study of oral orismilast in adult patients with moderate to severe psoriasis.
Hellerup, Denmark, 2 January 2022 – UNION therapeutics A/S, a privately held, multi-asset, clinical stage, pharmaceutical development company focused on immunology and infectious diseases, announced today that results of an epidemiological analysis using nationwide UK Kidney Association registry data on COVID-19 cases and COVID-19-associated mortality in dialysis and kidney transplant patients have been published in the peer-reviewed journal Transplantation. The analysis showed that two groups of immunocompromised patients (kidney patients on dialysis and kidney transplant patients) remain at increased risk of succumbing to COVID-19 despite all available countermeasures, including vaccination. This underlines the need for additional protection for this vulnerable population.
Hellerup, Denmark, 8 September 2022 – UNION therapeutics A/S (UNION), a privately-held, multi-asset, clinical stage, pharmaceutical development company focused on immunology and infectious diseases, today presented new data on pharmacological properties of orismilast from its preclinical studies with orismilast as well as not previously presented Phase 2a data on the safety and efficacy of orismilast IR formulation at the 31st EADV (European Academy of Dermatology and Venereology) Congress at 7-10 September 2022 in Milan, Italy.
Hellerup, Denmark, 1 September 2022 – UNION therapeutics A/S (UNION), a privately-held, multi-asset, clinical stage, pharmaceutical development company focused on immunology and infectious diseases, today announced the implementation of Treatment Extension to the ongoing OSIRIS Phase 2a study with orismilast MR tablet for the treatment of patients with mild to severe HS following approval granted by the Danish Medicines Agency and Ethics Committee. With the Treatment Extension, patients who have completed the OSIRIS study may continue treatment with orismilast MR tablets for a period of 52 weeks.